Facebook tracking pixelLeukocytoclastic Vasculitis - AI-Powered ICD-10 Documentation
D69.0
ICD-10-CM
Leukocytoclastic Vasculitis

Understand leukocytoclastic vasculitis diagnosis, symptoms, and treatment. Find information on clinical documentation, ICD-10 codes (L95.0, L95.1, D69.0), SNOMED CT codes, and medical coding for accurate healthcare billing and reimbursement. Learn about skin biopsy, histopathology, purpura, palpable purpura, and differential diagnoses for effective patient care and optimal coding practices. Explore resources for healthcare professionals, including dermatologists, rheumatologists, and medical coders.

Also known as

Hypersensitivity Vasculitis
Cutaneous Small-Vessel Vasculitis

Diagnosis Snapshot

Key Facts
  • Definition : Inflammation of small blood vessels in the skin, often causing palpable purpura.
  • Clinical Signs : Raised purple-red spots or bumps, usually on legs, that may itch or burn.
  • Common Settings : Drug reactions, infections (e.g., strep throat), autoimmune diseases, or idiopathic.

Related ICD-10 Code Ranges

Complete code families applicable to AAPC D69.0 Coding
D69.0

Allergic purpura

Inflammation of small blood vessels often triggered by an allergic reaction.

L95.0

Pigmented purpuric dermatosis

Chronic skin condition causing purplish spots, often on the lower legs.

M31.0

Hypersensitivity angiitis

Inflammation of small blood vessels due to an exaggerated immune response.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the leukocytoclastic vasculitis caused by a drug?

  • Yes

    Drug specified?

  • No

    Associated with systemic disease?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Inflammation of small blood vessels in the skin
IgA-mediated vasculitis affecting skin, joints, GI, kidneys
Systemic vasculitis with granulomatous inflammation

Documentation Best Practices

Documentation Checklist
  • Leukocytoclastic vasculitis diagnosis: Confirmed with skin biopsy.
  • Clinical findings: Palpable purpura, lower extremity distribution.
  • Histopathology: Neutrophils, fragmented nuclei, vessel wall damage.
  • Exclude other vasculitides: ANCA, cryoglobulins, infections ruled out.
  • ICD-10-CM: M31.8 (Other specified vasculitides) documented.

Coding and Audit Risks

Common Risks
  • Specificity Coding

    Coding LCV without specifying the cause (e.g., drug-induced, infection-related) leads to inaccurate data and potential DRG misassignment.

  • Clinical Validation

    Lack of clear clinical documentation supporting LCV diagnosis (e.g., biopsy, symptoms) can cause claim denials and compliance issues.

  • Conflicting Data

    Discrepancies between clinical notes, lab results, and coded diagnoses for LCV can raise red flags for audits and impact reimbursement.

Mitigation Tips

Best Practices
  • Thorough H&P crucial for LCV diagnosis: ICD-10 M31.8, document purpura characteristics.
  • Skin biopsy confirms LCV diagnosis, improves CDI, ensures compliance: LOINC 45892-4.
  • Identify triggers (meds, infections) for LCV: ICD-10 codes, precise documentation essential.
  • For LCV management, document treatment, response for optimal coding, billing compliance.
  • Regular follow-up, monitor LCV progression for accurate coding, improved patient outcomes.

Clinical Decision Support

Checklist
  • 1. Palpable purpura: documented, location specified?
  • 2. Skin biopsy ordered: confirms LCV diagnosis?
  • 3. Infection ruled out: relevant tests performed?
  • 4. Medication review: drug-induced vasculitis considered?

Reimbursement and Quality Metrics

Impact Summary
  • Leukocytoclastic Vasculitis reimbursement: ICD-10-CM M31.8, accurate coding impacts payment, enhances revenue cycle.
  • Quality metrics impact: Vasculitis diagnosis accuracy affects hospital reporting, influences quality scores, value-based care.
  • Coding accuracy: Precise documentation of LCV type (e.g., IgA) improves claims processing, minimizes denials, optimizes reimbursement.
  • Hospital reporting: Accurate LCV coding supports data analysis, population health management, and resource allocation.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Quick Tips

Practical Coding Tips
  • Code M31.0 for LCV, not symptoms
  • Document skin biopsy findings
  • Specify drug-induced LCV if applicable
  • Query physician for IgA vasculitis detail
  • Consider D69.0 for LCV, no other dx

Documentation Templates

Patient presents with complaints consistent with possible leukocytoclastic vasculitis (LCV).  Symptoms include palpable purpura, predominantly on the lower extremities, noted as small, raised, erythematous lesions.  The patient also reports mild pruritus associated with the rash.  Onset of symptoms was approximately one week ago, with gradual worsening.  No fever, chills, or systemic symptoms are reported.  Review of systems is otherwise unremarkable.  Medical history includes hypertension, managed with lisinopril.  No known drug allergies.  Physical examination confirms the presence of palpable purpura, with no evidence of ulceration or necrosis.  Differential diagnoses include Henoch-Schonlein purpura, drug-induced vasculitis, and other causes of cutaneous vasculitis.  A skin biopsy is planned to confirm the diagnosis of leukocytoclastic vasculitis and evaluate the extent of vascular inflammation.  Laboratory studies, including a complete blood count (CBC) with differential, comprehensive metabolic panel (CMP), urinalysis (UA), and inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), have been ordered.  Depending on biopsy results and clinical presentation, treatment options may include conservative management with supportive care, topical corticosteroids, or systemic therapy with corticosteroids or other immunosuppressants.  Patient education provided regarding the condition, potential complications, and importance of follow-up care.  ICD-10 code M31.8 (Other specified vasculitides) will be considered pending biopsy confirmation.  Appropriate CPT codes for the skin biopsy and laboratory studies will be applied.  Follow-up scheduled in one week to review biopsy results and discuss further management.